secwatch.observer — SEC 8-K summary
======================================

Issuer:     HOOKIPA Pharma Inc. (HOOK)
CIK:        0001760542
Form:       8-K
Filed at:   2024-05-23T23:59:59+00:00
Accession:  0001104659-24-064762
Event type: other_material
Sentiment:  positive
Materiality: 0.65
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

HOOKIPA reports HB-200 + pembro 53% ORR in CPS≥20; Phase 2/3 to start Q4 2024
-----------------------------------------------------------------------------

- Updated data from 42 first-line HPV16+ HNSCC patients: ORR 53%, CR 18%, DCR 82% in CPS≥20 subgroup.
- Median follow-up 5.6 months; grade ≥3 TRAEs in 14% of patients, no treatment-related deaths.
- Neoadjuvant HB-200 + chemo showed deep responses in 81% (17/21) of HPV16+ oropharyngeal cancer patients.
- HB-700 preclinical data induced KRAS mutation-specific T cell responses; Phase I planned for KRAS-mutated cancers.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1760542/000110465924064762/0001104659-24-064762-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1760542/000110465924064762/tm2415416d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-24-064762

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer